BioLargo’s subsidiary Clyra Medical secures over $1 million in direct investments

BioLargo's Advanced Oxidation System (AOS) Test Data Shows Breakthrough
BioLargo Reports Record Results
BioLargo Tops $1M in Annual Revenues for First Time
BioLargo, Inc.’s CEO Discusses Business Milestones and FDA Progress with Uptick Newswire
BioLargo Letter to Stockholders Details Company’s Recent Milestones and Successes
BioLargo Closes Bridge Financing with TRITON FUNDS LP
BioLargo acquires breakthrough stem cell therapy technology to expand medical product portfolio
BioLargo CEO Dennis Calvert Reports Breakthrough Commercial Success
BIOLARGO ANNOUNCES PARTICIPATION AT THE 20TH ANNUAL GLOBAL INVESTMENT CONFERENCE IN NEW YORK CITY
BioLargo Announces Craft Brewery Pre-Commercial Pilot Study Project Funded by ICP
Dennis Calvert, CEO of BioLargo, Inc., Returns to Uptick Newswire’s Stock Day Podcast
BioLargo Achieves Record Product Sales and Revenues – Marching to First Industry-Wide Adoption
Dennis Calvert, CEO of BioLargo, Inc., Returns to Uptick Newswire’s Stock Day Podcast to Discuss the
BioLargo continuing to improve balance sheet by converting debt to equity
Dennis Calvert, CEO of BioLargo, Inc., Returns to Uptick Newswire’s Stock Day Podcast
BioLargo, Inc. to Present at the 8th Annual LD Micro Invitational
BioLargo Achieves Record Product Sales and Revenues in Q1 2018
Press Release: BioLargo reduces balance sheet liabilities by more than $5,400,000
BioLargo, Inc. CEO Dennis Calvert Joins Everett Jolly on Uptick Newswire’s “Stock Day” Podcast
